REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in the Angiogenesis, Exudation, and Degeneration 2021 conference on February 12-13, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in the Angiogenesis, Exudation, and Degeneration 2021 conference on February 12-13, 2021. Two oral presentations will showcase advancements in gene therapy for eye diseases:
- Subretinal Gene Therapy for Exudative AMD by Allen C. Ho, M.D. on February 13 at 9:15 a.m. ET
- Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy by Peter A. Campochiaro, M.D. on February 13 at 9:45 a.m. ET
These presentations highlight the company's innovative approaches using its NAV® Technology Platform.
Positive
- Participation in a significant conference indicates ongoing research and development.
- Presentations by notable experts may enhance company credibility and visibility.
Negative
- None.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was +3.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conference taking place virtually from February 12 to 13, 2021.
The presentations will be as follows:
Presentation Title: Subretinal Gene Therapy for Exudative AMD
Presenter: Allen C. Ho, M.D., Director of Retina Research at Wills Eye Hospital and Mid Atlantic Retina
Date/Time: Saturday, February 13, 2021, 9:15 a.m. ET
Presentation Title: Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy
Presenter: Peter A. Campochiaro, M.D., Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
Date/Time: Saturday, February 13, 2021, 9:45 a.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Trademarks referenced herein are registered trademarks of REGENXBIO.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-angiogenesis-exudation-and-degeneration-2021-conference-301222819.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.